Brain metastasis was a common metastasis site and leading cause of death in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors had improved survival of NSCLC patients with positive drive gene. It also brings good news to NSCLC patients with positive drive gene and brain metastases. However, there is still no effective treatment for NSCLC patients with drive gene-negative and brain metastases. In recent years, immunotherapy has made breakthrough progress and become important first and second line treatment options of NSCLC especially in patients with drive gene-negative. The role of immunotherapy in specific populations of NSCLC-brain metastasis patients, especially drive gene-negative patients has become the focus of attention. In this report, we review the research progress of immunotherapy in NSCLC with brain metastases, especially in driver-negative patients, analyze the limitations of existing research and future challenge. .
【中文题目：驱动基因阴性非小细胞肺癌脑转移免疫治疗的研究进展】 【中文摘要：脑转移是非小细胞肺癌（non-small cell lung cancer, NSCLC）常见的转移部位和导致死亡的主要原因。酪氨酸激酶抑制剂（tyrosine kinase inhibitor, TKI）改善了驱动基因阳性NSCLC患者的生存，同时也为驱动基因阳性NSCLC脑转移患者带来了福音，然而对于驱动基因阴性脑转移NSCLC仍然缺少有效的治疗手段。近年来，免疫靶向治疗取得突破性进展，成为晚期NSCLC，尤其是驱动基因阴性患者一、二线治疗选择。免疫靶向治疗在NSCLC的特殊人群——脑转移患者尤其是驱动基因阴性患者中发挥怎样的作用已经成为研究者关注的焦点。本文将总结免疫靶向治疗在NSCLC脑转移尤其是驱动基因阴性患者中的研究进展，分析现有研究的局限和未来面临的挑战。 】 【中文关键词：肺肿瘤；脑转移；免疫检查点抑制剂；驱动基因阴性】.
Keywords: Brain metastases; Driver gene negative; Immune checkpoint inhibitor; Lung neoplasms.